Literature DB >> 8745869

Optimizing inhaled drug delivery in patients with asthma.

C Jackson1, B Lipworth.   

Abstract

Successful management of asthmatic patients depends on achieving adequate delivery of inhaled drugs to the lung. This assumes particular importance for inhaled corticosteroids where the therapeutic goal should be to achieve a high ratio of airway anti-inflammatory efficacy to local and systemic side effects. The availability of user-friendly inhaler devices requires a critical appraisal of their effectiveness and an evaluation of whether improved lung deposition of anti-asthma drugs translates into improved clinical efficacy. There is evidence to suggest that the routine use of large-volume spacers for inhaled corticosteroids may not be the best first-line option, in that reduced drug delivery is associated with multiple actuations, inhalation delay and the presence of static electricity. Breath-actuated pressurized aerosol devices or dry powder inhaler devices may be a better option for many asthmatic patients, although the efficiency of drug delivery varies considerably between these devices. There is good evidence with a reservoir dry powder inhaler device to show that improved lung deposition translates into better therapeutic response, both in terms of beta 2-agonist and corticosteroid delivery. For inhaled corticosteroids, such as fluticasone propionate and budesonide, there is evidence to show that systemic bioactivity is mainly determined by lung bioavailability rather than gastrointestinal bioavailability, because of the absence of first-pass metabolism of these drugs in the lung. There is also evidence to show that the greater glucocorticoid potency of fluticasone propionate translates directly into greater systemic bioactivity, but not into enhanced efficacy, at doses above 1 mg daily. The use of efficient delivery systems, such as the reservoir dry powder inhaler device, may not only improve control of asthma and compliance with therapy, but may also allow dose reduction ('step-down' therapy) and hence may possibly reduce overall prescribing costs in the long term.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8745869      PMCID: PMC1239475     

Source DB:  PubMed          Journal:  Br J Gen Pract        ISSN: 0960-1643            Impact factor:   5.386


  26 in total

1.  Comparison of the extrapulmonary beta2-adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose-inhaler and modified actuator device.

Authors:  D M Newnham; D G McDevitt; B J Lipworth
Journal:  Br J Clin Pharmacol       Date:  1993-11       Impact factor: 4.335

2.  An audit of inhaler technique among asthma patients of 34 general practitioners.

Authors:  S Hilton
Journal:  Br J Gen Pract       Date:  1990-12       Impact factor: 5.386

3.  The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler.

Authors:  S Pedersen; G Steffensen; S V Ohlsson
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

4.  Comparison of bronchodilator responses and deposition patterns of salbutamol inhaled from a pressurised metered dose inhaler, as a dry powder, and as a nebulised solution.

Authors:  B M Zainudin; M Biddiscombe; S E Tolfree; M Short; S G Spiro
Journal:  Thorax       Date:  1990-06       Impact factor: 9.139

5.  The effect of delay, multiple actuations and spacer static charge on the in vitro delivery of budesonide from the Nebuhaler.

Authors:  P W Barry; C O'Callaghan
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

6.  Problems patients have using pressurized aerosol inhalers.

Authors:  G K Crompton
Journal:  Eur J Respir Dis Suppl       Date:  1982

7.  Improvement of pressurised aerosol deposition with Nebuhaler spacer device.

Authors:  S P Newman; A B Millar; T R Lennard-Jones; F Morén; S W Clarke
Journal:  Thorax       Date:  1984-12       Impact factor: 9.139

8.  Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid.

Authors:  A Ryrfeldt; P Andersson; S Edsbäcker; M Tönnesson; D Davies; R Pauwels
Journal:  Eur J Respir Dis Suppl       Date:  1982

9.  Use of spacers to facilitate inhaled corticosteroid treatment of asthma.

Authors:  J H Toogood; J Baskerville; B Jennings; N M Lefcoe; S A Johansson
Journal:  Am Rev Respir Dis       Date:  1984-05

10.  High-dose inhaled steroids in asthmatics: moderate efficacy gain and suppression of the hypothalamic-pituitary-adrenal (HPA) axis. Research Council of the Norwegian Thoracic Society.

Authors:  J Boe; P Bakke; T Rødølen; E Skovlund; A Gulsvik
Journal:  Eur Respir J       Date:  1994-12       Impact factor: 16.671

View more
  4 in total

1.  Steroids in exacerbations of asthma: tablets or inhalers?

Authors:  C Griffiths
Journal:  Thorax       Date:  1996-11       Impact factor: 9.139

2.  Respiratory drug delivery devices.

Authors:  W Lenney
Journal:  Br J Gen Pract       Date:  1996-08       Impact factor: 5.386

3.  Inhaled drug delivery in asthma patients.

Authors:  W Lenney
Journal:  Br J Gen Pract       Date:  1996-12       Impact factor: 5.386

Review 4.  Patients' perspectives and preferences in the choice of inhalers: the case for Respimat(®) or HandiHaler(®).

Authors:  Pieter Nicolaas Richard Dekhuijzen; Federico Lavorini; Omar S Usmani
Journal:  Patient Prefer Adherence       Date:  2016-08-18       Impact factor: 2.711

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.